Suppliers / Wavelength Enterprises

Wavelength Enterprises

Israel Updated 9 July 2026

Wavelength Enterprises is an API manufacturer based in Israel. It holds 136 active US drug master files across a filed portfolio of 29 molecules. Its GMP standing is certified by EMA and MFDS (Korea). Its most recent recorded inspection, by US FDA, closed on 14 December 2022 as NAI.

136
active US DMFs
0
valid CEPs
2
registered plants 1 with an FDA FEI number
0
filings across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
4 of 4 confirmed
EU GMP
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Inspection history

  • 14 December 2022 NAI US FDA
  • 12 July 2018 NAI US FDA
  • 14 March 2013 VAI US FDA
  • 4 February 2010 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Israel, Israel 3002806718
Beer Sheva, Israel Not on file

Filings and GMP by regulator

Regulator Filings GMP certificates
EMA None 3
MFDS (Korea) None 2

Questions about Wavelength Enterprises

Does Wavelength Enterprises hold a US DMF or a CEP?
Wavelength Enterprises holds 136 active US drug master files. A drug master file is a submission to the FDA describing how an ingredient is made; a CEP is the EDQM's certificate that the substance meets its European Pharmacopoeia monograph. Both are filings rather than approvals.
Is Wavelength Enterprises FDA-registered?
One site operated by Wavelength Enterprises carries an FDA establishment identifier (FEI), which means it is registered with the FDA as a drug establishment. Registration is not the same as approval or inspection clearance.
How did Wavelength Enterprises's last inspection go?
The most recent inspection on record closed on 14 December 2022 as NAI (No Action Indicated: nothing objectionable was found). 4 inspections are on file.
Where does Wavelength Enterprises manufacture?
2 registered sites are on record, in Israel (Israel and Beer Sheva). Every site is listed on this page with the register it came from.
What does Wavelength Enterprises make?
29 molecules are on record against Wavelength Enterprises, including Cetirizine, Cisatracurium, Granisetron and Mometasone Furoate. Each links through to that molecule's full manufacturer list.
Which regulators recognise Wavelength Enterprises's GMP?
Current GMP certificates are on record from EMA and MFDS (Korea). GMP recognition covers the manufacturing site, separately from any filing on the substance itself.

Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.

Comparing suppliers?

Choose your molecules and target markets. Wavelength Enterprises comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • 7 active litigation matters are on record.
  • The most recent inspection outcome was NAI, on 14 December 2022.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates